NJ-OPENGEAR
7.6.2022 14:02:36 CEST | Business Wire | Press release
Opengear , a Digi International company (NASDAQ, DGII, www.digi.com/ ) and leading network resilience solutions provider, announced today that it is launching its new family of console managers, the CM8100. As the latest addition to its award-winning Smart OOBTM Console Server family, the CM8100 delivers a comprehensive solution, adding NetOps capabilities to existing Smart OOB features that simplify connectivity to IT equipment. Moreover, it provides resilient and secure remote access to infrastructure devices while enhancing security and automation for better smart out-of-band management.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220607005005/en/
“IT infrastructure needs to be resilient and easy to manage without relying on the network to manage the network,” says Gary Marks, President of Opengear. “Whether IT teams need to bring up new devices, manage existing ones or remediate outages, they must have resilient access to the network from anywhere. Regardless of the state of the production network, Opengear’s CM8100 provides engineers with the remote and reliable connectivity they need to be successful. It is yet another milestone in our long line of solutions designed to help engineers overcome today’s challenges such as travel requirements, security restrictions, and a lack of connectivity.”
CM8100 highlights:
- Hosts up to 48 managed serial connected devices
- Hardware-based TPM 2.0 security module providing data encryption and secure boot
- Open architecture REST API based firmware supporting automation tools, Docker, and Python scripting
- Four times faster than the previous generation while maintaining power-efficient and passively cooled operation up to 50C
- Dual AC power supplies with independent monitoring and alerting
The Opengear platform and CM8100 enhance console access with modern automation capabilities. The CM8100 also helps IT personnel remotely provision, manage and remediate devices. Likewise, it enables remote access to even the most sprawling and complex infrastructure, such as switches, routers, PDUs, firewalls, and other critical data center equipment. Additionally, CM8100 appliances establish secure VPN tunnels which connect IT, staff, to remote devices. This provides local access to Ethernet and RS-232 console ports via standard UTP patch cables. The resilient connection of the CM8100 is available to either IT staff or applications to configure managed devices.
“Nearly every enterprise is familiar with the ‘3 a.m.’ call about a down server or a network device but driving or even flying to a data center or remote site can be time-consuming and expensive,” adds Marks. “More than half of IT outages cost over $100,000 , so network issues must get fixed quickly. However, if engineers can’t access the network remotely and lack visibility, they will arrive at the site without the right tools or replacement devices to be successful in one trip. With the Opengear platform, IT personnel have the visibility to ascertain the problem from afar and also the access to remediate the outage remotely, saving considerable time and resources.”
For more information about the CM8100, visit https://opengear.com/products/cm8100-console-server/ .
To learn more about Opengear, visit: www.opengear.com .
About Opengear
Opengear, a Digi International company, delivers secure, resilient access and automation to support critical IT infrastructure, even when the network is down. Provisioning, orchestration, and remote management of network devices through innovative software and appliances enable technical staff to reliably and efficiently manage data centers and remote network locations. Opengear solutions are trusted by global organizations across financial, digital communications, retail and manufacturing industries. The company is headquartered in New Jersey, with R&D centers in Silicon Valley and Brisbane, Australia. Opengear was acquired by Digi International in 2019, bringing together two organizations with a deep commitment to providing the best products, software and services that meet the demands of mission-critical networks. For more information, please visit www.opengear.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220607005005/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
